KLOW

KLOW is a vendor name for a four-peptide mixture, GHK-Cu, KPV, BPC-157, and TB-500, usually sold as an 80 mg total vial. The commonly stated split (GHK-Cu 50 mg, the other three at 10 mg each) makes GHK-Cu about 62% of the vial by mass, not an equal fourth. No study has ever tested the four together in any system, and no published work addresses what GHK-Cu’s bound copper does to the other three peptides sitting in the same solution.

Research snapshot

Peptide category	Four-component peptide blend (GHK-Cu + KPV + BPC-157 + TB-500)
Primary research interest	Skin, gut, and general recovery (as marketed; not established for the combination)
Highest available evidence	None for the four-component blend itself; the closest adjacent data is a two-component (BPC-157 + TB-500) animal study
Human research available	No, zero human data exists for the four-component combination
Development status	Not a formulated drug product; a compounding/vendor mixture only
Regulatory status	None of the four components approved for human use anywhere; BPC-157, TB-500 and injectable GHK-Cu nominations were withdrawn at FDA in April 2026; none is approved

Technical identity (composition)

Primary name	KLOW
Alternative names	None beyond the component-based name itself
Composition	GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg, commonly sold as an 80 mg total vial, reconstituted in 3 mL
Share of vial by mass	GHK-Cu ~62%, BPC-157 ~13%, TB-500 ~13%, KPV ~13%
Peptide sequence	Not applicable, a multi-component mixture; see each component’s own entry for its sequence
Molecular formula	Not applicable, a multi-component mixture
CAS Registry Number	Not applicable, a multi-component mixture, not a single registered substance
Chemical modifications	Not applicable at the blend level; see each component’s own entry
Peptide class	Vendor-formulated multi-peptide mixture
Primary biological target	Multiple, inherits each component’s own separately-proposed target (see each component’s entry)
Developer or originator	Not a formal pharmaceutical development program, a research-chemical/compounding vendor mixture
Development status	Not in any clinical development pathway

What it is

KLOW is a vendor name for four peptides in a single vial: GHK-Cu, KPV, BPC-157 and TB-500. The name is an acronym of the components as suppliers order them. It is usually sold as an 80 mg total-peptide vial reconstituted in 3 mL.

The commonly stated split is GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. That makes GHK-Cu roughly 62 percent of the vial by mass, which is worth registering, because most descriptions of KLOW present the four as though they were comparable contributors.

At that concentration, one insulin unit of the reconstituted vial delivers about 167 micrograms of GHK-Cu. The copper alone, at roughly 16 percent of GHK-Cu by mass, works out to about 26 micrograms of elemental copper per unit.

The copper problem

This is the part no other page on this blend covers, and it is the most substantive thing to say about it.

GHK-Cu is not a peptide alone. It is a peptide holding a copper ion, and its copper binding is strong enough that it can strip copper from albumin transport sites. It also silences copper redox activity while bound, which is one of the properties its literature is built on.

Put that in a vial with three other peptides and two questions follow immediately. Does the copper stay on the GHK, or does some of it transfer to, or interact with, BPC-157, TB-500 or KPV? And does the presence of free or loosely held copper accelerate degradation of the other three, given that copper catalyses oxidation and that all three are peptides in aqueous solution?

Nobody has published on either question. Not in a formulation study, not in a stability study, not anywhere. The GHK-Cu literature has no work on multi-peptide co-formulation at all, and the BPC-157, TB-500 and KPV literatures contain no work on copper exposure in solution.

Separately, closely related copper tripeptides act as peroxidase mimics and generate reactive oxygen species in the presence of ascorbate and oxygen. Whether GHK-Cu does that in a shared vial is untested.

Potential benefits and research applications

Skin, gut, and general recovery (the marketed premise)

What is being investigated: nothing, specific to this four-component combination, no study has tested it. How the effect might occur: by combining each component’s separately proposed mechanism, GHK-Cu’s tissue-remodeling signaling, KPV’s anti-inflammatory melanocortin activity, BPC-157’s and TB-500’s proposed tissue-repair effects. Evidence: none for the combination. The closest available data point is the two-component BPC-157/TB-500 study discussed on the Wolverine entry, which found no added benefit from combining those two alone, a result that predates and doesn’t support extending the logic to four components. Strength: none established. Limitation: four compounds each with individually incomplete evidence do not add up to one compound with established efficacy.

Component-level claims (inherited by association, not established for the blend)

GHK-Cu is often the most heavily marketed component by mass share, with claims that trace mostly to conference material rather than controlled human trials. KPV, BPC-157, and TB-500 each carry their own separately documented, generally preliminary evidence bases. None of that evidence transfers automatically to a four-peptide mixture that has never itself been tested.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objective	Route reported	Amount reported	Frequency reported	Reported duration	Evidence or source category
Skin, gut, and recovery (blend as sold)	Subcutaneous	10 units (~0.10 mL) of reconstituted vial	Once daily	4–6 weeks on, 2–4 off	Community/vendor reported
GHK-Cu delivered per dose	Subcutaneous	~1.67 mg	Once daily	4–6 weeks	Community/vendor reported (derived from vial math)
BPC-157, TB-500, KPV delivered per dose (each)	Subcutaneous	~333 mcg each	Once daily	4–6 weeks	Community/vendor reported (derived from vial math)

Not consistently reported: any dosage for the four-component combination from a controlled study of any kind, human or animal. Checking the delivered amounts against each peptide’s own separately-circulating convention shows a mismatch: the GHK-Cu figure (~1.67 mg) and the BPC-157 figure (~333 mcg) land inside their own usual ranges, but the TB-500 figure (~333 mcg/day) is far below its own ~2–5 mg weekly convention, and the KPV figure (~333 mcg/day) is above its own ~200–500 mcg convention, a discrepancy no vendor material addresses.

What is known about the combination

Nothing. No study has tested these four components together in any system, in any species. No clinical trial exists, no registered trial exists, and no preclinical combination study exists.

The closest thing in the record is the rat Achilles study that tested two of the four, BPC-157 and TB-500, and found the combination no better than TB-500 alone.

What the component evidence says

Each component has its own entry. The short version, because the blend is often described as though four promising compounds were being stacked:

• GHK-Cu, at 62 percent of the vial, is the one with a real randomised placebo-controlled human trial. That trial found it no better than placebo in 86 patients with venous ulcers, and every positive human claim for it traces to conference abstracts, a defunct journal, a book chapter or a press release.
• KPV has no human trial at all, published or registered, and FDA said the same in its own 2026 review. Most of its encouraging animal data involves nanoparticle delivery rather than free peptide.
• BPC-157 has no identified receptor after roughly 230 papers, 77 percent of them from one laboratory, and its three human reports come from one clinic with no control group.
• TB-500 is a fragment, not thymosin beta-4, has no human study of any kind, and was inactive in the one wound assay that tested it directly.

Four compounds with no established efficacy do not become one compound with established efficacy.

Regulatory status

None of the four is an approved drug anywhere. GHK-Cu, BPC-157 and the TB-500 fragment were each the subject of FDA nominations that were later withdrawn, with immunogenicity noted as the concern. For GHK-Cu, FDA’s 503A categories page dated May 14, 2026 lists it in Category 1 (substances under evaluation) except for injectable routes, so the injectable form this blend uses has no active nomination, and FDA says it intends to consult its advisory committee on GHK-Cu before the end of February 2027.

On 23 July 2026 the Pharmacy Compounding Advisory Committee recommended BPC-157, TB-500 and KPV for the 503A compounding list in a single grouped vote, 8 to 6 with one abstention, against FDA staff in each case. The vote is non-binding, and a proposed rule, public comment and a final rule would have to come first. As of mid-August 2026 reporting, FDA had not acted, and news reports on 7 to 8 October describe administration plans for temporary sales of some unapproved peptides without naming them. GHK-Cu was not among the substances voted on, so the one ingredient that makes up most of a KLOW vial has no such recommendation. See the pages for BPC-157, KPV and TB-500 for each regulatory file.

On anti-doping, TB-500 is named in WADA section S2.3 and prohibited at all times. BPC-157 and KPV fall under class S0 as non-approved substances.

One naming note

KLOW, GLOW and Wolverine are searched together and routinely confused. GLOW is KLOW without the KPV. Wolverine contains no GHK-Cu and no KPV at all, only BPC-157 and TB-500. A product sold as one of the three may be any of them.

Related blends and where KLOW sits

KLOW is the four-ingredient member of a small family of vendor mixes. GLOW is the same formula without KPV. The GHK-Cu and BPC-157 pairing is two of those ingredients on their own. Wolverine is BPC-157 with TB-500 and no copper peptide, which is the only pairing here with any animal data behind it. Because each version changes the ratio of ingredients, vial arithmetic from one page does not carry over to another.

If you are trying to understand the numbers on this page, the guides on how a peptide is reconstituted, the difference between mg, mcg and syringe units and how to read a certificate of analysis explain the terms, and the reconstitution calculator does the arithmetic from values you enter. For the individual ingredients, see GHK-Cu, BPC-157, KPV, TB-500 and the full-length protein it is often confused with, thymosin beta-4.

Frequently asked questions

What is KLOW?

A vendor name for a mixture of GHK-Cu, KPV, BPC-157, and TB-500, usually sold as an 80 mg vial.

Is GHK-Cu really most of the vial?

Yes. At the commonly stated split, GHK-Cu is about 62% of the total mass, not an equal quarter.

Has the combination been studied?

No. No study, human or animal, has tested all four together.

What is the copper problem?

GHK-Cu carries a bound copper ion that is chemically reactive. Nobody has published on whether that copper stays bound or interacts with the other three peptides in the same vial over time.

How is it dosed?

Commonly 10 units (about 0.10 mL) of the reconstituted 80 mg/3 mL vial, once daily, a vendor convention with no study behind the schedule itself.

Is KLOW the same as GLOW?

No. GLOW is the same mixture without KPV.

Is KLOW the same as Wolverine?

No. Wolverine has neither GHK-Cu nor KPV.

Is it approved for any use?

No. None of the four components is an approved drug.

What remains unknown?

Whether the copper interacts with the other three peptides, whether the combination does anything as a whole, and whether the roughly 62% GHK-Cu ratio has any rationale.

Bottom line

KLOW is a vendor-invented combination, not a studied one. Its most distinctive open question, what GHK-Cu’s bound copper does to three other peptides sharing its vial, has never been addressed in the published literature, for this blend or for any other GHK-Cu multi-peptide co-formulation. The commonly circulated 10-unit daily dose delivers amounts that happen to land inside two of the four components’ own separate dosing conventions and outside the other two, a mismatch nobody selling the product accounts for. No trial of the four-component combination exists, and the components individually range from moderately documented (GHK-Cu, BPC-157) to essentially undocumented in humans (KPV, TB-500).